Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chlorogenic acid in preparing medicine for treating small cell lung cancer

A technology for small cell lung cancer and chlorogenic acid, which can be used in drug combinations, antitumor drugs, pharmaceutical formulations, etc., and can solve problems such as deletions, differences in pathological characteristics, and abnormal gene expression.

Active Publication Date: 2008-02-13
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] 2. Abnormal expression or deletion of genes
[0013] 2. Differences in pathological features
However, the TSNAs described in the literature are carcinogens in a broad sense, and the lung cancer involved is also a broad concept, or a superordinate concept of lung cancer, and it cannot explain the direct effect of chlorogenic acid on lung cancer
[0019] In summary, the effects of chlorogenic acid on lung cancer disclosed in the existing literature are limited to non-small cell lung cancer on the one hand, and there is no relevant report on the treatment of small cell lung cancer with chlorogenic acid.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chlorogenic acid in preparing medicine for treating small cell lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] [Example 1] Preparation of 0.9% sodium chloride injection for intravenous injection

[0029] Prescription one:

[0030] Chlorogenic acid with a purity greater than 95% 1.0g

[0031] Citric acid 1.0g

[0032] Sodium citrate 0.5g

[0033] Sodium chloride 18g

[0034] Water for injection 2000ml

[0035]

[0036] A total of 1,000 injections of 2ml were made according to the conventional operation of injections, each containing 1 mg of chlorogenic acid

[0037] Prescription two:

[0038] Chlorogenic acid with a purity greater than 95% 3000g

[0039] Sodium chloride 4500g

[0040] Water for injection 500000ml

[0041]

[0042] A total of 1,000 bottles of 500ml injections were made according to the conventional operation of injections, and each bottle contained 3 grams of chlorogenic acid

[0043] Stabilizers to prevent hydrolysis of chlorogenic acid: such as cyclodextrin i...

Embodiment 2

[0046] [Example 2] sterile powder injection containing sodium chloride

[0047] Prescription one:

[0048] Chlorogenic acid sterile powder with a purity greater than 95% 1.0g

[0049] Sodium chloride sterile powder 18g

[0050]

[0051] According to the routine operation of sterile powder injection, a total of 1000 2ml powder injections were made, each containing 1 mg of chlorogenic acid

[0052] Prescription two:

[0053] Chlorogenic acid sterile powder with a purity greater than 95% 3000g

[0054] Sodium chloride sterile powder 45g

[0055]

[0056] According to the routine operation of sterile powder injection, a total of 1000 5ml powder injections were made, each containing 3 grams of chlorogenic acid

[0057] Each formula product of Example 1 was freeze-dried by freeze-drying equipment to obtain a sterile freeze-dried powder injection of chlorogenic acid sodium chloride.

Embodiment 3

[0058] [Example 3] 5% glucose intravenous injection of chlorogenic acid:

[0059] Prescription one:

[0060] Chlorogenic acid (purity greater than 95%) 2.0g

[0061] Citric acid 1.0g

[0062] Sodium citrate 0.5g

[0063] Glucose 100g

[0064] Water for injection 2000ml

[0065]

[0066] A total of 1,000 injections of 2ml were made according to the conventional operation of injections, each containing 2 mg of chlorogenic acid

[0067] Prescription two:

[0068] Chlorogenic acid (purity greater than 95%) 1500g

[0069] Glucose 1000g

[0070] Water for injection 20000ml

[0071]

[0072] A total of 1,000 20ml injections were made according to the conventional operation of injections, each containing 1.5 grams of chlorogenic acid

[0073] Prescription three:

[0074] Chlorogenic acid (purity greater than 95%) 3000g

[0075] Glucose 25000g

[0076] Water for injection 500000m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides function of the Chlorogenic acid in small cell lung cancer treatment drug preparation. The Chlorogenic acid of the present invention has prohibiting effect on small cell lung cancer. The drug can not only substitute some part of the chemotherapy, but can also reduce the complaint reaction caused by the chemotherapy in the patients. The Chlorogenic acid is a new treatment method and choice for small cell lung cancer.

Description

technical field [0001] The present invention relates to a new application of chlorogenic acid, specifically, the application of chlorogenic acid in the preparation of medicine for treating small cell lung cancer. Background technique [0002] The morbidity and mortality of lung cancer rank first in malignant tumors, which seriously threaten human life and health. Modern medicine believes that lung cancer is a clonal disease caused by cell mutation. In lung cancer tissue, one kind of malignant cell usually dominates. From the perspective of biological behavior, it can be divided into two main types, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), of which SCLC accounts for about 15% to 20%. [0003] There are significant differences between SCLC and NSCLC not only in chromosomes, genes, cell surface markers and other cellular molecular levels, but also in pathological features. The specific differences are as follows: [0004] 1. Differences at the ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61P35/00A61P11/00
Inventor 张洁徐小平包旭易大朝
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com